Finding the Earliest Signals: Our Biomarker Discovery Initiative
We are focused on developing novel diagnostic methods for challenging cancers. Our current flagship project targets the urgent need for early detection of Ovarian Cancer.
Quantum Biosciences is dedicated to addressing the critical need for early and accurate ovarian cancer detection. Through focused research and strategic collaborations, we are working to develop novel diagnostic tools that can identify the disease in its earliest stages, creating a new outlook for patient survival and treatment success.
The Urgent Need for Early Detection in Ovarian Cancer
Ovarian cancer is notoriously difficult to diagnose early due to its vague and often silent symptoms. By the time it is discovered, it has often progressed to advanced stages, making treatment more challenging and significantly impacting patient prognosis. The absence of reliable, non-invasive screening tools for the general population represents one of the most significant unmet needs in oncology today. Improving early detection is the single most important factor in changing the outcome for women affected by this devastating disease.
The Science: Analyzing Exosomes for Biomarker Signatures
Our scientific approach for the Ovarian Cancer project focuses on analyzing exosomes—nano-sized vesicles released by cells. These vesicles contain a rich cargo of proteins and genetic material that can create a unique signature, acting as a fingerprint for cellular health. By isolating and analyzing the specific contents of exosomes found in blood, we aim to identify the distinct signatures that signal the presence of ovarian cancer at its earliest stages.
The Goal: An Innovative Early Detection Kit
The primary goal of this research initiative is to translate our findings into an innovative diagnostic kit. We are developing a highly sensitive and specific assay designed for effective use in clinical settings. This tool aims to provide physicians with the ability to make timely and accurate diagnoses, building upon the latest advancements in molecular biology, data science, and diagnostic technology.
Building a Purpose-Driven Research Ecosystem
Our approach to ovarian cancer diagnostics is built on a purpose-driven ecosystem of clinical and research experts. This ecosystem includes a core research partnership with a professor at the MD Anderson Cancer Center , an advisory board of specialized oncologists we are actively recruiting , and vital links to hospitals in India, which provide access to diverse clinical settings and data. This collaborative structure ensures our research is both innovative and grounded in real-world patient needs.
Driving Progress from Research to Real-World Impact
This initiative is currently in the active research phase, with our team focused on developing the foundational data required to support a comprehensive Small Business Innovation Research (SBIR) grant proposal to the National Institutes of Health (NIH) and other leading scientific funding bodies. Securing this peer-reviewed funding is a key part of our strategy to validate our scientific approach and advance this diagnostic tool through development, clinical validation, and ultimately, into the hands of physicians to save lives. To achieve this, we are continuously seeking to engage with additional collaborators and advisors to strengthen our team.
Join Our Mission to Defeat Ovarian Cancer
If you are an oncologist, researcher, potential funding partner, or healthcare institution dedicated to improving outcomes for ovarian cancer, we invite you to connect with us. Together, we can make early detection a reality.